SI2276485T1 - Uporaba epotilona D pri zdravljenju Tau- povezanih bolezni, vključno z Alzheimerjevo boleznijo - Google Patents

Uporaba epotilona D pri zdravljenju Tau- povezanih bolezni, vključno z Alzheimerjevo boleznijo

Info

Publication number
SI2276485T1
SI2276485T1 SI200931008T SI200931008T SI2276485T1 SI 2276485 T1 SI2276485 T1 SI 2276485T1 SI 200931008 T SI200931008 T SI 200931008T SI 200931008 T SI200931008 T SI 200931008T SI 2276485 T1 SI2276485 T1 SI 2276485T1
Authority
SI
Slovenia
Prior art keywords
epothilone
disease
diseases including
associated diseases
including alzheimer
Prior art date
Application number
SI200931008T
Other languages
English (en)
Inventor
Charles F. Albright
Donna Marie Barten
Francis Y. Lee
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40887113&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2276485(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of SI2276485T1 publication Critical patent/SI2276485T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
SI200931008T 2008-04-24 2009-04-24 Uporaba epotilona D pri zdravljenju Tau- povezanih bolezni, vključno z Alzheimerjevo boleznijo SI2276485T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4772908P 2008-04-24 2008-04-24
EP09735906.1A EP2276485B1 (en) 2008-04-24 2009-04-24 Use of epothilone d in treating tau-associated diseases including alzheimer's disease
PCT/US2009/041634 WO2009132253A1 (en) 2008-04-24 2009-04-24 Use of epothelone d in treating tau-associated diseases including alzheimer's disease

Publications (1)

Publication Number Publication Date
SI2276485T1 true SI2276485T1 (sl) 2014-10-30

Family

ID=40887113

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200931008T SI2276485T1 (sl) 2008-04-24 2009-04-24 Uporaba epotilona D pri zdravljenju Tau- povezanih bolezni, vključno z Alzheimerjevo boleznijo

Country Status (26)

Country Link
US (3) US20090270465A1 (sl)
EP (1) EP2276485B1 (sl)
JP (1) JP5548675B2 (sl)
KR (1) KR20100137576A (sl)
CN (3) CN102076339A (sl)
AR (1) AR071598A1 (sl)
AU (1) AU2009240538B2 (sl)
BR (1) BRPI0911482A2 (sl)
CA (1) CA2722371C (sl)
CL (1) CL2009000990A1 (sl)
CY (1) CY1115617T1 (sl)
DK (1) DK2276485T3 (sl)
EA (1) EA021758B1 (sl)
ES (1) ES2501565T3 (sl)
HK (1) HK1153152A1 (sl)
HR (1) HRP20140783T1 (sl)
HU (1) HUE024506T2 (sl)
IL (1) IL208926A0 (sl)
MX (1) MX2010011209A (sl)
NZ (1) NZ588555A (sl)
PL (1) PL2276485T3 (sl)
PT (1) PT2276485E (sl)
SI (1) SI2276485T1 (sl)
TW (1) TWI472329B (sl)
WO (1) WO2009132253A1 (sl)
ZA (1) ZA201007460B (sl)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE027630T2 (en) 2006-04-07 2016-10-28 Vertex Pharma Modulators of ATP-binding cassette transporters
US7645789B2 (en) 2006-04-07 2010-01-12 Vertex Pharmaceuticals Incorporated Indole derivatives as CFTR modulators
US10022352B2 (en) 2006-04-07 2018-07-17 Vertex Pharmaceuticals Incorporated Modulators of ATP-binding cassette transporters
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
US20100184803A1 (en) * 2007-03-09 2010-07-22 Link Medicine Corporation Treatment of Lysosomal Storage Diseases
WO2009151683A2 (en) 2008-03-12 2009-12-17 Link Medicine Corporation Quinolinone farnesyl transferase inhibitors for the treatment of synucleinopathies and other indications
CA2722371C (en) 2008-04-24 2016-06-21 Bristol-Myers Squibb Company Use of epothelone d in treating tau-associated diseases including alzheimer's disease
AU2009313906A1 (en) * 2008-11-13 2010-05-20 Link Medicine Corporation Treatment of proteinopathies using a farnesyl transferase inhibitor
WO2010057006A1 (en) 2008-11-13 2010-05-20 Link Medicine Corporation Azaquinolinone derivatives and uses thereof
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
CA3108488A1 (en) 2010-04-22 2011-10-27 Vertex Pharmaceuticals Incorporated Process of producing cycloalkylcarboxamido-indole compounds
US8563593B2 (en) * 2010-06-08 2013-10-22 Vertex Pharmaceuticals Incorporated Formulations of (R)-1-(2,2-difluorobenzo[D] [1,3] dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide
EP2811980A4 (en) * 2012-01-31 2015-12-23 Cerulean Pharma Inc POLYMER-AGENT CONJUGATES, PARTICLES, COMPOSITIONS AND METHODS OF USE THEREOF
EP2870176A4 (en) 2012-07-03 2016-09-28 Univ Washington ANTIBODIES DIRECTED AGAINST TAU
EP2872122A1 (en) 2012-07-16 2015-05-20 Vertex Pharmaceuticals Incorporated Pharmaceutical compositions of (r)-1-(2,2-diflurorbenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration thereof
IL266286B2 (en) 2014-04-15 2023-11-01 Vertex Pharma Pharmaceutical preparations for the treatment of diseases related to cystic fibrosis transmembrane conductance regulator modulators
TWI734975B (zh) 2014-06-27 2021-08-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗-tau抗體
JP6321521B2 (ja) 2014-11-04 2018-05-09 Ｗｅｌｌ Ｓｔｏｎｅ 有限会社 タウ蛋白産生促進剤、タウ蛋白の欠乏に起因する疾患の治療薬・予防薬および治療用・予防用食品組成物
US11498974B2 (en) 2016-07-14 2022-11-15 Bioarctic Ab Brain delivery protein
CN114727995A (zh) * 2020-09-02 2022-07-08 北京华昊中天生物医药股份有限公司 优替德隆的固体口服制剂
CN113005086B (zh) * 2021-02-01 2022-10-28 中国科学院遗传与发育生物学研究所 埃博霉素D和Apol8在调控神经干细胞定向神经元分化中的应用

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2809918A (en) 1955-10-17 1957-10-15 Victor M Hermelin Sustained release pharmaceutical preparations
DE2010416B2 (de) 1970-03-05 1979-03-29 Hoechst Ag, 6000 Frankfurt Oral anwendbare Arzneiform mit Retardwirkung
US4728512A (en) 1985-05-06 1988-03-01 American Home Products Corporation Formulations providing three distinct releases
US4794001A (en) 1986-03-04 1988-12-27 American Home Products Corporation Formulations providing three distinct releases
US5225202A (en) 1991-09-30 1993-07-06 E. R. Squibb & Sons, Inc. Enteric coated pharmaceutical compositions
US5580898A (en) * 1994-05-24 1996-12-03 The Trustees Of The University Of Pennsylvania Method of stabilizing microtubules
EP1440973A3 (de) 1995-11-17 2004-10-20 Gesellschaft für biotechnologische Forschung mbH (GBF) Epothilonderivate, Herstellung und Mittel
US6242469B1 (en) 1996-12-03 2001-06-05 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6605599B1 (en) * 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
US6320045B1 (en) * 1997-12-04 2001-11-20 Bristol-Myers Squibb Company Process for the reduction of oxiranyl epothilones to olefinic epothilones
WO1999028324A1 (en) 1997-12-04 1999-06-10 Bristol-Myers Squibb Company A process for the reduction of oxiranyl epothilones to olefinic epothilones
IL138113A0 (en) 1998-02-25 2001-10-31 Sloan Kettering Inst Cancer Synthesis of epothilones, intermediates thereto and analogues thereof
US6498257B1 (en) * 1998-04-21 2002-12-24 Bristol-Myers Squibb Company 2,3-olefinic epothilone derivatives
US6380395B1 (en) * 1998-04-21 2002-04-30 Bristol-Myers Squibb Company 12, 13-cyclopropane epothilone derivatives
UA69413C2 (uk) 1998-05-22 2004-09-15 Брістол-Майерс Сквібб Компані Фармацевтична композиція, яка містить серцевину та ентеросолюбільну оболонку, фармацевтична композиція у вигляді сфероїдальних гранул, спосіб одержання сфероїдальних гранул та спосіб одержання фармацевтичної композиції
DE59911151D1 (de) 1998-07-27 2004-12-30 Joergen Brosow Sicherheitspapier sowie verfahren und vorrichtung zur prüfung der echtheit darauf aufgezeichneter urkunden
US6410301B1 (en) 1998-11-20 2002-06-25 Kosan Biosciences, Inc. Myxococcus host cells for the production of epothilones
KR100851418B1 (ko) 1998-11-20 2008-08-08 코산 바이오사이언시즈, 인코포레이티드 에포틸론 및 에포틸론 유도체의 생산을 위한 재조합 방법 및 물질
DE60006649T2 (de) * 1999-02-22 2004-09-30 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) C-21 modifizierte epothilone
US6998256B2 (en) 2000-04-28 2006-02-14 Kosan Biosciences, Inc. Methods of obtaining epothilone D using crystallization and /or by the culture of cells in the presence of methyl oleate
US8618085B2 (en) * 2000-04-28 2013-12-31 Koasn Biosciences Incorporated Therapeutic formulations of desoxyepothilones
JP2004516011A (ja) 2000-07-25 2004-06-03 コーサン バイオサイエンシーズ， インコーポレイテッド エポチロンのための発酵プロセス
JP3604337B2 (ja) * 2000-10-03 2004-12-22 古河電気工業株式会社 絶縁電線の製造方法
WO2002032844A2 (de) 2000-10-16 2002-04-25 Morphochem Ag Epothilone-synthesebausteine iii und iv: unsymmetrisch substituierte acyloine und acyloinderivate, verfahren zu deren herstellung sowie verfahren zur herstellung von epothilon b, d und epothilonderivaten
TW476749B (en) * 2000-11-17 2002-02-21 Nat Science Council Process for preparing 2,6-dimethylphenol
FR2817117B1 (fr) 2000-11-24 2005-11-04 Commissariat Energie Atomique Mammiferes non-humains transgeniques ou recombinants et leurs applications dans le criblage de medicaments utiles dans les desordres psychoactifs
WO2002058699A1 (en) 2001-01-25 2002-08-01 Bristol-Myers Squibb Company Pharmaceutical forms of epothilones for oral administration
EP1363619A2 (en) * 2001-02-02 2003-11-26 The Regents of the University of California Coumarin compounds as microtubule stabilizing agents and therapeutic uses thereof
CA2449077A1 (en) * 2001-06-01 2002-12-12 Gregory D. Vite Epothilone derivatives
KR20040088531A (ko) 2002-02-25 2004-10-16 코산 바이오사이언시즈, 인코포레이티드 2차 대사 동종체 분포 조절
US7082674B2 (en) * 2002-02-27 2006-08-01 Sumitomo Heavy Industries, Ltd. Method for winding a single coil of a coil unit for a linear motor
EP1340498A1 (en) * 2002-03-01 2003-09-03 Schering Aktiengesellschaft Use of epothilones in the treatment of brain diseases associated with proliferative processes
US6719540B2 (en) * 2002-03-12 2004-04-13 Bristol-Myers Squibb Company C3-cyano epothilone derivatives
WO2003077903A1 (en) * 2002-03-12 2003-09-25 Bristol-Myers Squibb Company C12-cyano epothilone derivatives
ES2323956T3 (es) 2002-07-15 2009-07-28 Helmholtz-Zentrum Fur Infektionsforschung Gmbh Macrociclos para el tratamiento del cancer.
WO2004016269A1 (en) 2002-08-17 2004-02-26 The Queens Universlty Of Belfast Use of vinca alkaloyds, taxane, cryptophycine, ephitoline or eleutherobine for treating alzheimer
RS20050235A (en) 2002-09-23 2007-06-04 Bristol Myers Squibb Company, Methods for the preparation, isolation and purification of epothilone b, and x-ray crystal structures of epothilone b
CA2520732C (en) * 2003-03-28 2012-12-04 Sloan-Kettering Institute For Cancer Research Migrastatin analogs and uses thereof
US6954131B2 (en) * 2003-04-02 2005-10-11 Illinois Tool Works Inc. Electrical reactor assembly having center taps
RU2358729C2 (ru) * 2003-10-09 2009-06-20 Козан Байосайенсиз, Инк. Терапевтические композиции
EP1559447A1 (en) 2004-01-30 2005-08-03 Institut National De La Sante Et De La Recherche Medicale (Inserm) Use of epothilones in the treatment of neuronal connectivity defects such as schizophrenia and autism
WO2006009178A1 (ja) 2004-07-20 2006-01-26 Toshinori Kato 生体機能診断装置、生体機能診断方法、生体用プローブ、生体用プローブ装着具、生体用プローブ支持具及び生体用プローブ装着支援具
US20060142393A1 (en) * 2004-09-16 2006-06-29 Sherman Matthew L Bis(thio-hydrazide amides) for treatment of hyperplasia
US8785451B2 (en) * 2006-08-21 2014-07-22 Synta Pharmaceuticals Corp. Compounds for the treatment of proliferative disorders
MX2009001877A (es) * 2006-08-21 2009-03-02 Synta Pharmaceuticals Corp Compuestos para el tratamiento de trastornos proliferativos.
JP2010501564A (ja) * 2006-08-21 2010-01-21 シンタ ファーマシューティカルズ コーポレーション 黒色腫を治療するためのビス（チオヒドラジドアミド）
CA2722371C (en) 2008-04-24 2016-06-21 Bristol-Myers Squibb Company Use of epothelone d in treating tau-associated diseases including alzheimer's disease

Also Published As

Publication number Publication date
US8673949B2 (en) 2014-03-18
CA2722371A1 (en) 2009-10-29
HRP20140783T1 (hr) 2014-09-12
MX2010011209A (es) 2010-11-12
KR20100137576A (ko) 2010-12-30
CL2009000990A1 (es) 2010-10-15
EA201001695A1 (ru) 2011-08-30
ES2501565T3 (es) 2014-10-02
AU2009240538B2 (en) 2014-08-07
US20140135367A1 (en) 2014-05-15
WO2009132253A1 (en) 2009-10-29
TWI472329B (zh) 2015-02-11
CN104116736A (zh) 2014-10-29
IL208926A0 (en) 2011-01-31
TW200948360A (en) 2009-12-01
JP2011522782A (ja) 2011-08-04
CN102076339A (zh) 2011-05-25
NZ588555A (en) 2012-06-29
EA021758B1 (ru) 2015-08-31
CY1115617T1 (el) 2017-01-04
CN104666297A (zh) 2015-06-03
AR071598A1 (es) 2010-06-30
DK2276485T3 (da) 2014-10-13
PL2276485T3 (pl) 2014-12-31
AU2009240538A1 (en) 2009-10-29
US20090270465A1 (en) 2009-10-29
HK1153152A1 (en) 2012-03-23
CA2722371C (en) 2016-06-21
US20110230528A1 (en) 2011-09-22
HUE024506T2 (en) 2016-01-28
EP2276485A1 (en) 2011-01-26
ZA201007460B (en) 2012-03-28
PT2276485E (pt) 2014-10-20
BRPI0911482A2 (pt) 2017-08-29
JP5548675B2 (ja) 2014-07-16
EP2276485B1 (en) 2014-07-16

Similar Documents

Publication Publication Date Title
PL2276485T3 (pl) Stosowanie epotilonu D w leczeniu chorób związanych z Tau, w tym choroby Alzheimera
IL264736B (en) Pharmaceutical preparations containing zonisamide for use in the treatment of diseases related to Alzheimer's disease
PL2104682T3 (pl) Diagnostyka i leczenie choroby Alzheimera i innych chorób neurodegeneracyjnych
IL219412A (en) Preparations containing Busimanden for use in the treatment of Alzheimer's or Alzheimer's disease
EP2312945A4 (en) PURE DERIVATIVES FOR THE TREATMENT OF MORBUS ALZHEIMER
EP2001503A4 (en) DIAGNOSIS AND TREATMENT OF MORBUS ALZHEIMER
EP2091566A4 (en) COMBINATION THERAPIES AGAINST ALZHEIMER DISEASE AND SIMILAR ILLNESSES
IL213259A0 (en) Composition for the use to treat alzheimer's disease
EP2151435A4 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF ALZHEIMER'S DISEASE
EP2382176A4 (en) USE OF CURCUMIN ANALOGUES CONTAINING NITROGEN FOR THE TREATMENT OF ALZHEIMER'S DISEASE
HUE043807T2 (hu) GLYX Alzheimer-kór, Parkinson-kór vagy Huntington-kór kezelésében történõ alkalmazásra
EP2297341A4 (en) METHOD AND COMPOSITIONS FOR TREATING MORBUS HUNTINGTON
EP2429992A4 (en) TREATMENT OF EASY COGNITIVE IMMUNITY AND MORBUS ALZHEIMER
EP2268647A4 (en) COMPOUNDS AND COMPOSITIONS FOR THE IDENTIFICATION AND TREATMENT OF MORBUS ALZHEIMER AND RELATED DISEASES
EP2312946A4 (en) PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ALZHEIMER'S DISEASE
EP2378879A4 (en) TRIAZONE DERIVATIVES FOR THE TREATMENT OF MORBUS ALZHEIMER
EP2306824A4 (en) IONTOPHORETIC DELIVERY OF CURCUMINE AND CURCUMINANALOGUE FOR THE TREATMENT OF MORBUS ALZHEIMER
PL2148667T3 (pl) Stosowanie pochodnych cycloheksanoheksolu w leczeniu chorób oczu
EP2320939A4 (en) TISSUE CALLICLE FOR THE TREATMENT OF PARKINSON DISEASE
EP2568811A4 (en) TREATMENT OF EASY COGNITIVE IMMUNITY AND MORBUS ALZHEIMER
PL1981515T3 (pl) Leczenie urazów i chorób mózgu za pomocą MAPC
EP2398789A4 (en) SPIROPYRROLIDINE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
EP2349308A4 (en) COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE
EP2391379A4 (en) COMPOUNDS AND METHOD FOR THE TREATMENT OF MORBUS ALZHEIMER
EP2375895A4 (en) METHOD OF TREATING ALZHEIMER'S DISEASE AND RELATED STATES